Results from EMBRACE Phase 2a study of emapalumab in interferon-gamma-driven sepsis presented at ISICEM

Swedish Orphan Biovitrum AB Sweden

Primary endpoint: improvement in organ function observed in 60% of patients receiving high-dose emapalumab vs 40% with standard of care plus placebo28-day mortality: 40% in the high-dose emapalumab group vs 52% in the placebo groupBiomarker response: high-dose emapalumab associated with faster reduction of pro-inflammatory biomarkers linked to interferon-gamma signallingEmapalumab was generally well toleratedView original content:https://www.prnewswire.co.uk/news-releases/results-from-embrace-phase-2a-study-of-emapalumab-in-interferon-gammadriven-sepsis-presented-at-isicem-302717345.html